Rhumbline Advisers Viking Therapeutics, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 130,445 shares of VKTX stock, worth $4.55 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

130,445

Previous 127,258 2.5%

Holding current value

$4.55 Million

Previous $6.75 Million 22.43%

% of portfolio

0.01%

Previous 0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$49.84 - $70.47 $158,840 - $224,587	3,187 Added 2.5%	130,445 $8.26 Million
Q2 2024 Aug 01, 2024	SELL	$47.39 - $80.2 $798,284 - $1.35 Million	-16,845 Reduced 11.69%	127,258 $6.75 Million
Q1 2024 May 09, 2024	BUY	$17.4 - $94.5 $259,451 - $1.41 Million	14,911 Added 11.54%	144,103 $11.8 Million
Q4 2023 Feb 08, 2024	SELL	$9.24 - $19.64 $15,671 - $33,309	-1,696 Reduced 1.3%	129,192 $2.4 Million
Q3 2023 Nov 09, 2023	BUY	$10.92 - $16.0 $33,404 - $48,944	3,059 Added 2.39%	130,888 $1.45 Million
Q2 2023 Aug 08, 2023	BUY	$14.84 - $24.79 $1.9 Million - $3.17 Million	127,829 New	127,829 $2.07 Million
Q2 2022 Aug 11, 2022	SELL	$2.11 - $3.15 $195,139 - $291,321	-92,483 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$3.0 - $4.88 $49,197 - $80,027	-16,399 Reduced 15.06%	92,483 $277,000
Q4 2021 Feb 10, 2022	SELL	$4.6 - $6.72 $2,971 - $4,341	-646 Reduced 0.59%	108,882 $501,000
Q3 2021 Nov 12, 2021	BUY	$5.58 - $7.04 $18,849 - $23,781	3,378 Added 3.18%	109,528 $688,000
Q2 2021 Aug 05, 2021	SELL	$5.19 - $6.73 $44,639 - $57,884	-8,601 Reduced 7.5%	106,150 $636,000
Q1 2021 May 06, 2021	SELL	$5.74 - $9.67 $31,627 - $53,281	-5,510 Reduced 4.58%	114,751 $726,000
Q4 2020 Feb 10, 2021	BUY	$5.3 - $6.71 $71,963 - $91,108	13,578 Added 12.73%	120,261 $677,000
Q3 2020 Nov 12, 2020	SELL	$5.73 - $8.11 $80,729 - $114,261	-14,089 Reduced 11.67%	106,683 $621,000
Q2 2020 Aug 13, 2020	BUY	$4.35 - $8.08 $49,650 - $92,225	11,414 Added 10.44%	120,772 $871,000
Q1 2020 May 06, 2020	BUY	$3.45 - $7.95 $30,187 - $69,562	8,750 Added 8.7%	109,358 $512,000
Q4 2019 Feb 05, 2020	BUY	$6.38 - $8.73 $6,290 - $8,607	986 Added 0.99%	100,608 $807,000
Q3 2019 Oct 23, 2019	BUY	$6.55 - $8.6 $51,109 - $67,105	7,803 Added 8.5%	99,622 $685,000
Q2 2019 Aug 14, 2019	BUY	$7.67 - $10.63 $107,855 - $149,479	14,062 Added 18.08%	91,819 $762,000
Q1 2019 May 01, 2019	BUY	$7.58 - $9.94 $38,028 - $49,868	5,017 Added 6.9%	77,757 $773,000
Q4 2018 Jan 31, 2019	BUY	$7.16 - $16.21 $199,040 - $450,621	27,799 Added 61.86%	72,740 $556,000
Q3 2018 Nov 07, 2018	BUY	$9.7 - $19.65 $32,048 - $64,923	3,304 Added 7.94%	44,941 $783,000
Q2 2018 Aug 06, 2018	BUY	$3.88 - $12.74 $161,551 - $530,455	41,637 New	41,637 $395,000

Others Institutions Holding VKTX

# of Institutions

469

Shares Held

63.2M

Call Options Held

5.76M

Put Options Held

3.39M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $2.68B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Viking Therapeutics, Inc. Transaction History